https://www.selleckchem.com/pr....oducts/i-bet151-gsk1
INTRODUCTION Mastocytosis is associated with mast cell (MC) mediator-related symptoms for which limited therapies are available. Our aim was to assess the efficacy and safety of omalizumab in the treatment of MC mediator-related symptoms in adult patients with mastocytosis. METHODS We included all published studies and case reports by searching MEDLINE, EMBASE, Web of Science and Cochrane up to April 2019. All adult patients diagnosed with mastocytosis according to WHO criteria and treated with omalizumab were included. Pri
Like
Comment
Share
